| Literature DB >> 34311704 |
Vivienne C Bachelet1, María S Navarrete2, Constanza Barrera-Riquelme2, Víctor A Carrasco2, Matías Dallaserra3, Rubén A Díaz2, Álvaro A Ibarra2, Francisca J Lizana2, Nicolás Meza-Ducaud2, Macarena G Saavedra2, Camila Tapia-Davegno2, Alonso F Vergara2, Julio Villanueva3,4.
Abstract
BACKGROUND: The Iberoamerican Cochrane Network is currently developing an extensive project to identify Spanish-language journals that publish original clinical research in Spain and Latin America. The project is called BADERI (Database of Iberoamerican Essays and Journal) and feeds the research articles, mainly randomised clinical trials (RCTs), into CENTRAL (Cochrane Collaboration Central Register of Controlled Trials). This study aims to assess the quality of reporting of RCTs published in Spanish and Latin American journals for three clinical fields and assess changes over time.Entities:
Mesh:
Year: 2021 PMID: 34311704 PMCID: PMC8314448 DOI: 10.1186/s12874-021-01337-3
Source DB: PubMed Journal: BMC Med Res Methodol ISSN: 1471-2288 Impact factor: 4.615
The instrument used to extract data on CONSORT variables (items)
| CONSORT item | # | Description and definition | Scoring |
|---|---|---|---|
| Title | 1a | Identification as a randomised trial in the title | 1 = word random appears in the title 0 = no word "random" appears |
| Abstract | 1b | Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) | 1 = Structured abstract 0 = No structured abstract |
| Trial design | 3a | Description of trial design (such as parallel, factorial) including allocation ratio (ex-split-mouth) | 1 = well described design 0 = not well-described design |
| Participants | 4a | Eligibility criteria for participants | 1 = specified 0 = not specified |
| 4b | Settings (A) and locations (B) where the data were collected | 2 = A and B 1 = A or B 0 = not specified | |
| Interventions | 5 | The interventions for each group (A) with sufficient details to allow replication, including how and when they were actually administered (B) (i.e. "usual care" for control group not enough)] | 2 = A and B 1 = A, but only one group with details 0 = only A or only one group without details |
| Outcomes | 6a | Completely defined pre-specified primary (A) and secondary outcome (B) measures, including how and when they were assessed (C) | 2 = A and B and C 1 = A or B (no distinction) + C 0 = A or B, no C |
| Sample size | 7a | How sample size was determined | 1 = specified 0 = not specified |
| Sequence generation | 8a | The method used to generate the random allocation sequence | 1 = specified 0 = not specified |
| Allocation concealment mechanism | 9 | The mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned | 1 = steps for concealment specified 0 = concealment not specified |
| Implementation | 10 | Who generated the random allocation sequence (A), who enrolled participants (B), and who assigned participants to interventions (C) | 2 = A and B and C 1 = (A and B) or (A and C) 0 = A missing |
| Blinding | 11a | If done, who was blinded (A) after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how (B) | 2 = (A and B) OR reason why the study is open label 1 = declares who is blinded but no details as how 0 = declares the study blind but no who nor how |
| Statistical methods | 12a | Statistical methods used to compare groups for primary and secondary outcomes | 2 = states full stats method for each outcome 1 = states stats methods for primary outcome 0 = states stats methods vaguely |
| Participant flow (a diagram is strongly recommended) | 13a | For each group, the numbers of participants who were randomly assigned (A), received intended treatment (B) and were analysed for the primary outcome (C) | 2 = A and B and C (narrative in text OR complete flow diagram) 1 = A or B or C missing (only one missing) 0 = only one reported or no info at all |
| 13b | For each group, losses (A) and exclusions (B) after randomisation, together with reasons (C) | 2 = A and B and C 1 = A or B or C missing (only one missing) 0 = only one reported, or no info at all | |
| Recruitment | 14a | Dates defining the periods of recruitment (A) and follow-up (B) | 2 = A and B reported 1 = A or B reported 0 = none reported |
| Baseline data | 15 | A table showing baseline demographic and clinical characteristics for each group | 1 = "Table 1" present 0 = "Table 1" not present |
| Numbers analysed | 16 | For each group, number of participants (denominator) included in each analysis (A) and whether the analysis was by original assigned groups (B) [ITT or Per Protocol] | 2 = A and B 1 = A or B 0 = not stated |
| Outcomes and estimation | 17a | For each primary and secondary outcome, | 2 = A and B and C 1 = A or B or C missing (only one missing) 0 = only one reported or none |
| Harms | 19 | All important harms or unintended effects in each group | 1 = harms described 0 = harms not described |
| Registration | 23 | Registration number and name of | 1 = present 0 = absent |
| Protocol | 24 | Where the full trial | 1 = present 0 = absent |
| Funding | 25 | Sources of | 1 = present 0 = absent |
| Additional item | AIa | Total number of patients randomised | Annotate sample size |
| Additional item | AIb | Conflict of interest statement | 1 = present 0 = absent |
| Additional item | AIc | Ethics review | 1 = present 0 = absent |
| Additional item | AId | Language of article | Spanish/English/Portuguese |
Fig. 1Flow diagram of study selection. Figure prepared by the authors based on study results
Distribution of journals and included RCTs by country and clinical field
| Country | Dentistry | Neurology | Geriatrics | |||
|---|---|---|---|---|---|---|
| Argentina | 2 | 6 | 1 | 2 | 1 | 1 |
| Chile | 8 | 62 | 2 | 4 | 0 | 0 |
| Colombia | 7 | 24 | 0 | 0 | 0 | 0 |
| Ecuador | 0 | 0 | 1 | 4 | 0 | 0 |
| Mexico | 8 | 19 | 3 | 22 | 0 | 0 |
| Peru | 5 | 16 | 0 | 0 | 0 | 0 |
| Spain | 16 | 143 | 6 | 47 | 2 | 29 |
| Uruguay | 1 | 1 | 0 | 0 | 0 | 0 |
| Venezuela | 5 | 11 | 1 | 1 | 0 | 0 |
Mean CONSORT compliance scores by country and clinical field. Score scale from 0 to 34 (n = 392)
| Country | Dentistry | Neurology mean ± SD (RCTs) | Geriatrics mean ± SD (RCTs) | Average score mean ± SD | Overall average score |
|---|---|---|---|---|---|
| Argentina | 12.8 ± 5.3 (6) | 11.5 ± 5.0 (2) | 9.0 (1) | 12.1 ± 5.3 | 12.6 ± 5.1 |
| Chile | 13.7 ± 6.0 (62) | 12.3 ± 3.4 (4) | - | 13.6 ± 6.0 | |
| Colombia | 14.8 ± 5.0 (24) | - | - | 14.8 ± 5.0 | |
| Ecuador | - | 12.3 ± 2.6 (4) | - | 12.3 ± 2.6 | |
| Mexico | 10.4 ± 4.6 (19) | 11.4 ± 5.5 (22) | - | 10.9 ± 4.6 | |
| Peru | 10.1 ± 4.2 (16) | - | - | 10.1 ± 4.2 | |
| Spain | 13.2 ± 5.0 (143) | 11.5 ± 4.8 (47) | 11.6 ± 6.0 (29) | 12.7 ± 5.0 | |
| Uruguay | 6.0 (1) | - | - | 6.0 | |
| Venezuela | 11.1 ± 4.5 (11) | 17.0 (1) | - | 11.1 ± 4.5 |
Empty cells indicate that there were no RCTs includedSD Standard deviation
Fig. 2Distribution of CONSORT compliance scores (n = 392)
Overall mean scores over three time periods and by clinical fields
| Time period | No. of RCTs | Dentistry | Neurology | Geriatrics | Overall score |
|---|---|---|---|---|---|
| 1990 to 2010 | 189 | 10.5 ± 4.2 | 11.4 ± 5.1 | 9.5 ± 4.8 | 10.7 ± 4.5 |
| 2011 to 2014 | 99 | 13.6 ± 5.0 | 11.6 ± 3.6 | 13.9 ± 5.9 | 13.3 ± 4.9 |
| 2015 to 2018 | 104 | 15.7 ± 4.9 | 13.4 ± 4.6 | 13.0 ± 7.3 | 15.3 ± 5.1 |
SD Standard deviation
Fig. 3RCTs published and the mean score, by year
The proportion of RCTs that comply with each CONSORT item included for analysis in the study, by region, and the overall compliance (n = 392)
| Consort item and number | Latin America (%) | Spain (%) | All (%) | ||
|---|---|---|---|---|---|
| Title & abstract | 1a | Title | 16 | 30 | 24 |
| 1b | Abstract | 55 | 82 | 70 | |
| Methods | 3a | Trial design | 58 | 55 | 56 |
| 4a | Participants | 72 | 82 | 78 | |
| 4b | Settings | 43 | 44 | 43 | |
| 5 | Interventions | 88 | 84 | 86 | |
| 6a | Outcomes | 21 | 22 | 22 | |
| Randomisation | 7a | Sample size | 22 | 19 | 20 |
| 8a | Sequence generation | 28 | 35 | 32 | |
| 9 | Allocation concealment | 12 | 11 | 11 | |
| 10 | Implementation | 3 | 0 | 1 | |
| 11a | Blinding | 24 | 18 | 21 | |
| 12a | Statistical methods | 44 | 37 | 40 | |
| Results | 13a | Participant flow | 35 | 28 | 31 |
| 13b | Losses & exclusions | 20 | 19 | 19 | |
| 14a | Dates of recruitment | 5 | 4 | 4 | |
| 15 | Baseline data | 29 | 39 | 34 | |
| 16 | Numbers analysed | 15 | 15 | 15 | |
| 17a | Outcomes & estimation | 3 | 5 | 4 | |
| 19 | Harms | 26 | 29 | 28 | |
| Other information | 23 | Registration | 2 | 5 | 4 |
| 24 | Protocol | 0 | 1 | 1 | |
| 25 | Funding | 28 | 25 | 26 | |
Fig. 4Overall compliance with CONSORT for six essential items, by periods
Fig. 5Sample size by year of publication (n = 377)